These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38532812)

  • 1. The Impact of Intravenous Ferric Carboxymaltose on Reverse Electrical Remodeling Following Cardiac Resynchronization Therapy.
    Bozcali E; Polat V
    Acta Cardiol Sin; 2024 Mar; 40(2):182-190. PubMed ID: 38532812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.
    Martens P; Dupont M; Dauw J; Nijst P; Herbots L; Dendale P; Vandervoort P; Bruckers L; Tang WHW; Mullens W
    Eur Heart J; 2021 Dec; 42(48):4905-4914. PubMed ID: 34185066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy.
    Martens P; Dupont M; Dauw J; Somers F; Herbots L; Timmermans P; Verwerft J; Mullens W
    ESC Heart Fail; 2019 Dec; 6(6):1208-1215. PubMed ID: 31562751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reverse electrical remodeling by cardiac resynchronization therapy: prevalence and clinical impact.
    Sebag FA; Martins RP; Defaye P; Hidden-Lucet F; Mabo P; Daubert JC; Leclercq C
    J Cardiovasc Electrophysiol; 2012 Nov; 23(11):1219-27. PubMed ID: 22697464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of intravenous ferric carboxymaltose on right ventricular function - insights from the IRON-CRT trial.
    Martens P; Dupont M; Dauw J; Nijst P; Bertrand PB; Tang WHW; Mullens W
    Eur J Heart Fail; 2022 Jun; 24(6):1106-1113. PubMed ID: 35303390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between electrical and mechanical remodeling after cardiac resynchronization therapy: systematic review and meta-analysis of observational studies.
    Pilecky D; Duray GZ; Elsner D; Israel CW; Erath-Honold JW; Vamos M
    Heart Fail Rev; 2022 Nov; 27(6):2165-2176. PubMed ID: 35670890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of iron deficiency on cardiac resynchronization therapy: results from the RIDE-CRT Study.
    Lacour P; Dang PL; Morris DA; Parwani AS; Doehner W; Schuessler F; Hohendanner F; Heinzel FR; Stroux A; Tschoepe C; Haverkamp W; Boldt LH; Pieske B; Blaschke F
    ESC Heart Fail; 2020 Jun; 7(3):1072-1084. PubMed ID: 32189474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac resynchronization therapy in patients with heart failure and narrow QRS complexes (≤ 130 ms): role of speckle tracking echocardiography and different interventricular (VV) pacing intervals.
    Kantharia BK; Singh A; Narasimhan B; Wu L; Karnik R; Chutani S; Shah AN
    J Interv Card Electrophysiol; 2022 Mar; 63(2):369-377. PubMed ID: 34138397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction.
    López-Vilella R; Lozano-Edo S; Arenas Martín P; Jover-Pastor P; Ezzitouny M; Sorolla Romero J; Calvo Asensio M; Martínez-Solé J; Guerrero Cervera B; Sánchez Martínez JC; Donoso Trenado V; Sánchez-Lázaro I; Martinez Dolz L; Almenar Bonet L
    ESC Heart Fail; 2022 Feb; 9(1):133-145. PubMed ID: 34964300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron therapy and severe arrhythmias in HFrEF: rationale, study design, and baseline results of the RESAFE-HF trial.
    Bakogiannis C; Mouselimis D; Tsarouchas A; Papadopoulos CE; Theofillogiannakos EK; Lechat E; Antoniadis AP; Pagourelias ED; Kelemanis I; Tzikas S; Fragakis N; Efthimiadis GK; Karamitsos TD; Doumas M; Vassilikos VP
    ESC Heart Fail; 2023 Apr; 10(2):1184-1192. PubMed ID: 36647691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).
    Kutyifa V; Kloppe A; Zareba W; Solomon SD; McNitt S; Polonsky S; Barsheshet A; Merkely B; Lemke B; Nagy VK; Moss AJ; Goldenberg I
    J Am Coll Cardiol; 2013 Mar; 61(9):936-44. PubMed ID: 23449428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy.
    Huang HT; Huang JL; Lin PL; Lee YH; Hsu CY; Chung FP; Liao CT; Chiou WR; Lin WY; Liang HW; Chang HY
    ESC Heart Fail; 2022 Dec; 9(6):3825-3835. PubMed ID: 35945811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
    van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
    Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of QRS complex duration and morphology on left ventricular reverse remodelling and left ventricular function improvement after cardiac resynchronization therapy.
    van der Bijl P; Khidir M; Leung M; Mertens B; Ajmone Marsan N; Delgado V; Bax JJ
    Eur J Heart Fail; 2017 Sep; 19(9):1145-1151. PubMed ID: 28176418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The QRS narrowing index predicts reverse left ventricular remodeling following cardiac resynchronization therapy.
    Rickard J; Popovic Z; Verhaert D; Sraow D; Baranowski B; Martin DO; Lindsay BD; Varma N; Tchou P; Grimm RA; Wilkoff BL; Chung MK
    Pacing Clin Electrophysiol; 2011 May; 34(5):604-11. PubMed ID: 21276023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac resynchronization therapy modulates peripheral sympathetic activity.
    Xiao PL; Cai C; Zhang P; DeSimone CV; Ernst DK; Yin YH; Chen PS; Cha YM
    Heart Rhythm; 2020 Jul; 17(7):1139-1146. PubMed ID: 32113897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design.
    Miñana G; Cardells I; Palau P; Llàcer P; Fácila L; Almenar L; López-Lereu MP; Monmeneu JV; Amiguet M; González J; Serrano A; Montagud V; López-Vilella R; Valero E; García-Blas S; Bodí V; de la Espriella-Juan R; Sanchis J; Chorro FJ; Bayés-Genís A; Núñez J;
    Clin Cardiol; 2018 Jun; 41(6):729-735. PubMed ID: 29607528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID.
    Nouhravesh N; Garg J; Rockhold FW; De Pasquale CG; O'Meara E; Lewis GD; Butler J; Harrington J; Ezekowitz JA; Ponikowski P; Troughton RW; Wong YW; Blackman N; Numan S; Adamczyk R; Hernandez AF; Mentz RJ
    Eur J Heart Fail; 2024 Jun; ():. PubMed ID: 38896006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
    Filippatos G; Ponikowski P; Farmakis D; Anker SD; Butler J; Fabien V; Kirwan BA; Macdougall IC; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA;
    Circulation; 2023 May; 147(22):1640-1653. PubMed ID: 37051919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Iron Deficiency on Response to and Remodeling After Cardiac Resynchronization Therapy.
    Martens P; Verbrugge F; Nijst P; Dupont M; Tang WH; Mullens W
    Am J Cardiol; 2017 Jan; 119(1):65-70. PubMed ID: 27780556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.